Article
Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients.
Oncotarget - 27 Dec 2016
Fu Tao, Liu Yanliang, Li Kai, Wan Weiwei, Pappou Emmanouil P, Iacobuzio-Donahue Christine A, Kerner Zachary, Baylin Stephen B, Wolfgang Christopher L, Ahuja Nita
Abstract excerpt
We previously developed a novel tumor subtype classification model for duodenal adenocarcinomas based on a combination of the CpG island methylator phenotype (CIMP) and MLH1 methylation status. Here, we tested the prognostic value of this model in stage II colorectal cancer (CRC) patients. Tumors were assigned to CIMP+/MLH1-unmethylated (MLH1-U), CIMP+/MLH1-methylated (MLH1-M), CIMP-/MLH1-U, or CIMP-/MLH1-M...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
